| 2001 | Biological Grandparent (maternal): Alzheimer's / Other Dementia | GCST90475484 | 8.72 |
| 2002 | Irritable bowel syndrome mixed subtype | GCST90243959 | 8.71 |
| 2003 | CD63/EDAR ratio | GCST90313864 | 8.71 |
| 2004 | Ratio of polyunsaturated fatty acids to monounsaturated fatty acids | GCST90092940 | 8.71 |
| 2005 | Parkinson's disease | FING00001150 | 8.70 |
| 2006 | CLEC4D/CLEC6A ratio | GCST90314109 | 8.69 |
| 2007 | EIF4G1/HEXIM1 ratio | GCST90314635 | 8.69 |
| 2008 | SNAP29/SPARC ratio | GCST90315860 | 8.68 |
| 2009 | Cholesteryl Esters in Small HDL | GCST90499382 | 8.68 |
| 2010 | LEPR levels | GCST90469756 | 8.67 |
| 2011 | Frequency of light DIY in last 4 weeks | Physical activity | UKBB00000264 | 8.67 |
| 2012 | F-dessert liking (derived food-liking factor) | GCST90094754 | 8.66 |
| 2013 | SNAP23/TBL1X ratio | GCST90315856 | 8.65 |
| 2014 | Abdominal subcutaneous adipose tissue normalized | GCST90267348 | 8.65 |
| 2015 | BCAN/NPTXR ratio | GCST90313482 | 8.64 |
| 2016 | TFPI levels | GCST90470839 | 8.64 |
| 2017 | Seronegative rheumatoid arthritis | FING00001296 | 8.64 |
| 2018 | Plateletcrit | GCST004607 | 8.64 |
| 2019 | SIT1 levels | GCST90470644 | 8.64 |
| 2020 | GDI2 levels | GCST90088004 | 8.64 |
| 2021 | SPARC/ZBTB16 ratio | GCST90315875 | 8.63 |
| 2022 | Phospholipids to total lipids ratio in large VLDL | GCST90092877 | 8.63 |
| 2023 | ANGPT1/PDGFA ratio | GCST90313266 | 8.62 |
| 2024 | KITLG/PLTP ratio | GCST90315252 | 8.61 |
| 2025 | wg rh intensity-contrast temporalpole | GCST90003859 | 8.60 |
| 2026 | Basophil percentage of white cells | GCST004631 | 8.59 |
| 2027 | IDP T1 FAST ROIs L cerebellum I-IV | GCST90002562 | 8.59 |
| 2028 | ANGPT1/EGF ratio | GCST90313264 | 8.59 |
| 2029 | ECE1 levels | GCST90469061 | 8.59 |
| 2030 | MYO9B levels | GCST90469982 | 8.59 |
| 2031 | T1 FreeSurfer a2009s lh S central thickness | GCST90384786 | 8.58 |
| 2032 | MYOM3 levels | GCST90469986 | 8.58 |
| 2033 | Speech-in-noise perception | GCST90044776 | 8.58 |
| 2034 | Oranges liking | GCST90094807 | 8.58 |
| 2035 | Follicular cysts of skin and subcutaneous tissue | FING00000547 | 8.58 |
| 2036 | GRN levels | GCST90469404 | 8.56 |
| 2037 | PTPN1/WWP2 ratio | GCST90315746 | 8.56 |
| 2038 | HPCAL1/MPIG6B ratio | GCST90315073 | 8.55 |
| 2039 | CD58/ROR1 ratio | GCST90313854 | 8.55 |
| 2040 | Treatment/medication code - ibuprofen | Medications | UKBB00000847 | 8.55 |
| 2041 | IGF1 levels | GCST90102623 | 8.55 |
| 2042 | CCN2/HBEGF ratio | GCST90313713 | 8.54 |
| 2043 | OMD/SPP1 ratio | GCST90315586 | 8.54 |
| 2044 | MMP8/OLR1 ratio | GCST90315464 | 8.54 |
| 2045 | DDX58 levels | GCST90468977 | 8.53 |
| 2046 | BSG/LAMP3 ratio | GCST90313533 | 8.53 |
| 2047 | Free cholesterol in IDL | GCST90497561 | 8.53 |
| 2048 | BST2/CEACAM1 ratio | GCST90313537 | 8.52 |
| 2049 | Cholesterol esters in very small VLDL | GCST90500749 | 8.50 |
| 2050 | RNASE1 levels | GCST90470476 | 8.50 |
| 2051 | Omega-6 fatty acid levels | GCST90502518 | 8.50 |
| 2052 | Monounsaturated fatty acid levels | GCST90502358 | 8.49 |
| 2053 | 1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels | GCST90200685 | 8.49 |
| 2054 | CST3/IL18BP ratio | GCST90314294 | 8.48 |
| 2055 | NPTX1 levels | GCST90470078 | 8.47 |
| 2056 | FKBP4/WWP2 ratio | GCST90314842 | 8.47 |
| 2057 | HDL x anxiety interaction (2df test) | GCST90570665 | 8.47 |
| 2058 | ABL1/DNMBP ratio | GCST90313149 | 8.47 |
| 2059 | Blood cell traits latent factor 5 (platelet) | GCST90559247 | 8.45 |
| 2060 | HBEGF/SDC4 ratio | GCST90315037 | 8.45 |
| 2061 | AXIN1/NFATC1 ratio | GCST90313415 | 8.45 |
| 2062 | ECHS1 levels | GCST90469063 | 8.45 |
| 2063 | Ingrowing nail (PheCode 703.1) | GCST90476208 | 8.45 |
| 2064 | Reason for reducing amount of alcohol drunk - Other reason | Alcohol | UKBB00000735 | 8.44 |
| 2065 | Ulcerative ileocolitis | FING00001392 | 8.44 |
| 2066 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502554 | 8.43 |
| 2067 | FHIT/PMVK ratio | GCST90314822 | 8.43 |
| 2068 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 8.42 |
| 2069 | Triglycerides to total lipids ratio in medium VLDL | GCST90092927 | 8.42 |
| 2070 | Chronic ulcer of leg or foot (PheCode 707.2) | GCST90476218 | 8.42 |
| 2071 | Chronic diseases of tonsils and adenoids | FING00000283 | 8.41 |
| 2072 | IL17A levels | GCST90469558 | 8.39 |
| 2073 | Types of physical activity in last 4 weeks - Strenuous sports | Physical activity | UKBB00000874 | 8.39 |
| 2074 | FCER2/TCL1A ratio | GCST90314790 | 8.39 |
| 2075 | IDP dMRI TBSS ICVF Tapetum L | GCST90004374 | 8.39 |
| 2076 | ITGB1BP2 levels | GCST90012058 | 8.38 |
| 2077 | LAIR2 levels | GCST90469729 | 8.38 |
| 2078 | ADH4/DCXR ratio | GCST90313190 | 8.38 |
| 2079 | DPP7 levels | GCST90469035 | 8.37 |
| 2080 | TGFBR2/TNFRSF1A ratio | GCST90315918 | 8.37 |
| 2081 | Phospholipids in VLDL | GCST90500268 | 8.37 |
| 2082 | LMNB1 levels | GCST90469781 | 8.35 |
| 2083 | MVK/SERPINE1 ratio | GCST90315505 | 8.34 |
| 2084 | Total lipids in lipoprotein particles (UKB data field 23423) | GCST90269520 | 8.34 |
| 2085 | DTI TBSS L2 Posterior corona radiata R | GCST90384502 | 8.33 |
| 2086 | Postinfectious hypothyroidism | FING00001192 | 8.33 |
| 2087 | Bone marrow fat fraction of thoracic vertebra 8 | GCST90652380 | 8.33 |
| 2088 | SERPINB1/TMSB10 ratio | GCST90315830 | 8.33 |
| 2089 | WASHC3 levels | GCST90471069 | 8.32 |
| 2090 | Phenylalanine levels | GCST90499228 | 8.31 |
| 2091 | Linoleic acid to total fatty acids percentage | GCST90502320 | 8.31 |
| 2092 | IDP T1 FAST ROIs V cerebellum VIIIa | GCST90002579 | 8.30 |
| 2093 | Platelet crit | Blood count | UKBB00000647 | 8.30 |
| 2094 | Phospholipids to total lipids ratio in medium LDL | GCST90092913 | 8.30 |
| 2095 | C2/LILRB4 ratio | GCST90313554 | 8.30 |
| 2096 | MSRA/SNAP29 ratio | GCST90315500 | 8.29 |
| 2097 | COMP/MYOC ratio | GCST90314191 | 8.29 |
| 2098 | CEACAM8 levels | GCST90468698 | 8.29 |
| 2099 | CXCL5/SDC4 ratio | GCST90314353 | 8.29 |
| 2100 | MSTN levels | GCST90469953 | 8.29 |
| 2101 | Total lipids in small VLDL | GCST90499849 | 8.28 |
| 2102 | Aspartate aminotransferase levels | GCST90018724 | 8.28 |
| 2103 | Polyunsaturated fatty acid levels | GCST90502622 | 8.27 |
| 2104 | ITGB5/S100A4 ratio | GCST90315233 | 8.27 |
| 2105 | Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels | GCST90060270 | 8.27 |
| 2106 | SCARF2/TNFRSF21 ratio | GCST90315813 | 8.27 |
| 2107 | LAMA4/NID1 ratio | GCST90315272 | 8.26 |
| 2108 | FGF23 levels | GCST90012022 | 8.26 |
| 2109 | BACH1/CNST ratio | GCST90313436 | 8.25 |
| 2110 | Other systemic involvement of connective tissue (FG) | FING00001116 | 8.23 |
| 2111 | PCDH9 levels | GCST90470172 | 8.23 |
| 2112 | T1 FreeSurfer DK lh superiortemporal thickness | GCST90385651 | 8.23 |
| 2113 | ADGRG2/NRCAM ratio | GCST90313186 | 8.21 |
| 2114 | IL18 levels | GCST90469567 | 8.21 |
| 2115 | ASAH2 levels | GCST90242098 | 8.20 |
| 2116 | Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels | GCST90060298 | 8.20 |
| 2117 | CTSC/PLA2G15 ratio | GCST90314311 | 8.20 |
| 2118 | CD38/RELT ratio | GCST90313809 | 8.19 |
| 2119 | SSC4D/TNFSF10 ratio | GCST90315887 | 8.19 |
| 2120 | BMP6 levels | GCST90468454 | 8.19 |
| 2121 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 8.18 |
| 2122 | CD93/TNFRSF4 ratio | GCST90313922 | 8.18 |
| 2123 | NFASC levels | GCST90470031 | 8.18 |
| 2124 | SUGT1/TBL1X ratio | GCST90315897 | 8.17 |
| 2125 | DAB2/ZBTB16 ratio | GCST90314370 | 8.15 |
| 2126 | IDP dMRI ProbtrackX ICVF atr r | GCST90004378 | 8.14 |
| 2127 | F11R/PLXNA4 ratio | GCST90314724 | 8.14 |
| 2128 | Fibrosis and cirrhosis of liver | FING00000543 | 8.14 |
| 2129 | Illness, injury, bereavement, stress in last 2 years - None of the above | Mental health | UKBB00000339 | 8.14 |
| 2130 | SERPINE1/USP8 ratio | GCST90315835 | 8.13 |
| 2131 | Presence of cardiac and vascular implants and grafts | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000708 | 8.13 |
| 2132 | Stable angina pectoris | GCST90018695 | 8.13 |
| 2133 | ATP5IF1/HSPA1A ratio | GCST90313388 | 8.12 |
| 2134 | SPRY2/YTHDF3 ratio | GCST90315881 | 8.12 |
| 2135 | Length of working week for main job | Employment | UKBB00000405 | 8.12 |
| 2136 | Disorders of skin appendages | FING00000460 | 8.11 |
| 2137 | aparc-a2009s lh volume G-pariet-inf-Supramar | GCST90002950 | 8.10 |
| 2138 | IL1R1 levels | GCST90425563 | 8.09 |
| 2139 | MMP3 levels | GCST90012027 | 8.09 |
| 2140 | AIFM1/SIRT2 ratio | GCST90313221 | 8.08 |
| 2141 | Free cholesterol levels in VLDL | GCST90092998 | 8.08 |
| 2142 | Asthma mixed form (mode) (more control exclusions) | FING00000116 | 8.07 |
| 2143 | Degree of unsaturation | GCST90500175 | 8.06 |
| 2144 | NUCB2/TRIAP1 ratio | GCST90315577 | 8.05 |
| 2145 | WARS levels | GCST90471066 | 8.05 |
| 2146 | IDP T1 FAST ROIs R cerebellum VIIIa | GCST90002580 | 8.05 |
| 2147 | SOD3 levels | GCST90470706 | 8.05 |
| 2148 | LCN2/PGLYRP1 ratio | GCST90315306 | 8.04 |
| 2149 | BCL2L11/VASH1 ratio | GCST90313485 | 8.02 |
| 2150 | Etiocholanolone glucuronide levels | GCST90199964 | 8.02 |
| 2151 | LBR/LGALS8 ratio | GCST90315294 | 8.02 |
| 2152 | CLIP2/DAB2 ratio | GCST90314124 | 8.01 |
| 2153 | BTN2A1/SMOC2 ratio | GCST90313549 | 8.01 |
| 2154 | ICA1/MVK ratio | GCST90315108 | 8.01 |
| 2155 | CLEC1B/DKK1 ratio | GCST90314088 | 8.00 |
| 2156 | CCDC80 levels | GCST90468562 | 8.00 |
| 2157 | FCRL5/ICAM3 ratio | GCST90314802 | 8.00 |
| 2158 | CALCA levels | GCST90468528 | 8.00 |
| 2159 | SERPINA7 levels | GCST90470587 | 7.99 |
| 2160 | HSPA1A/MGLL ratio | GCST90315083 | 7.99 |
| 2161 | PCDH1/TNFRSF11A ratio | GCST90315608 | 7.99 |
| 2162 | TREML2 levels | GCST90470962 | 7.98 |
| 2163 | ALCAM/NOTCH1 ratio | GCST90313241 | 7.98 |
| 2164 | Omega-6 fatty acids to total fatty acids percentage | GCST90502544 | 7.96 |
| 2165 | CD48 levels | GCST90425676 | 7.96 |
| 2166 | Prescriptions - gliclazide | sulfonylurea,diabetes | UKBB00000684 | 7.96 |
| 2167 | AKT1S1/MAX ratio | GCST90313230 | 7.95 |
| 2168 | ANXA4/CA13 ratio | GCST90313290 | 7.95 |
| 2169 | Cholelithiasis | Disorders of gallbladder, biliary tract and pancreas | UKBB00000132 | 7.95 |
| 2170 | DSC2/EFEMP1 ratio | GCST90314555 | 7.94 |
| 2171 | GADD45GIP1 levels | GCST90469293 | 7.93 |
| 2172 | FBP1/GSTA1 ratio | GCST90314786 | 7.92 |
| 2173 | Saturated fatty acids levels | GCST90502670 | 7.91 |
| 2174 | STK11/USP8 ratio | GCST90315892 | 7.91 |
| 2175 | PEAR1/TREML2 ratio | GCST90315645 | 7.91 |
| 2176 | Alanine transaminase (ALT, mean, inv-norm transformed) | GCST90475112 | 7.91 |
| 2177 | MSRA/PRDX5 ratio | GCST90315497 | 7.89 |
| 2178 | Diacylglycerol_36:4_[M+H-H2O]1+ levels | GCST90060188 | 7.88 |
| 2179 | POSTN levels | GCST90470288 | 7.88 |
| 2180 | Liver volume (adjusted for height) | GCST90566819 | 7.87 |
| 2181 | Hyperlipidemia | GCST90090994 | 7.87 |
| 2182 | Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579) | GCST90269676 | 7.87 |
| 2183 | FGF2/HBEGF ratio | GCST90314811 | 7.86 |
| 2184 | CXCL1 levels | GCST90012019 | 7.86 |
| 2185 | Ganglion | FING00000563 | 7.85 |
| 2186 | PDGFB/SNAP29 ratio | GCST90315627 | 7.85 |
| 2187 | Urine X-24798 levels in chronic kidney disease | GCST90266802 | 7.84 |
| 2188 | CLU levels | GCST90468793 | 7.84 |
| 2189 | CREG1/NAAA ratio | GCST90314250 | 7.83 |
| 2190 | ITGB1/VASN ratio | GCST90315232 | 7.83 |
| 2191 | Alanine transaminase (ALT, minimum, inv-norm transformed) | GCST90475115 | 7.82 |
| 2192 | Degree of unsaturation | GCST90502233 | 7.82 |
| 2193 | ADAM8 levels | GCST90468220 | 7.81 |
| 2194 | Cholesterol, total | GCST002221 | 7.80 |
| 2195 | CASP3/LYN ratio | GCST90313635 | 7.80 |
| 2196 | SEMA4C levels | GCST90470572 | 7.79 |
| 2197 | Ulcerative colitis | GCST90476067 | 7.78 |
| 2198 | ENTPD6 levels | GCST90469122 | 7.78 |
| 2199 | TXNRD1 levels | GCST90470994 | 7.77 |
| 2200 | Retrobulbar neuritis in diseases classified elsewhere | FING00001265 | 7.77 |
| 2201 | FLT1/TGFB1 ratio | GCST90314857 | 7.75 |
| 2202 | F11R levels | GCST90469164 | 7.75 |
| 2203 | Volume of right paralaminar nucleus | GCST90475048 | 7.74 |
| 2204 | FCRL5 levels | GCST90469208 | 7.74 |
| 2205 | CLEC1B/HBEGF ratio | GCST90314092 | 7.73 |
| 2206 | Neuroticism | GCST002920 | 7.72 |
| 2207 | CD22/TCL1A ratio | GCST90313760 | 7.72 |
| 2208 | F2R/TMSB10 ratio | GCST90314738 | 7.72 |
| 2209 | KLK6/MOG ratio | GCST90315255 | 7.71 |
| 2210 | CCL3 levels | GCST90012055 | 7.69 |
| 2211 | IFNGR1/IL10RB ratio | GCST90315127 | 7.69 |
| 2212 | DTI autoptx MD unc r tract | GCST90385246 | 7.67 |
| 2213 | Docosahexaenoic acid to total fatty acids percentage | GCST90502285 | 7.67 |
| 2214 | aseg lh volume CerebralWhiteMatter | GCST90002615 | 7.66 |
| 2215 | FAM174A levels | GCST90241914 | 7.66 |
| 2216 | Lymphocyte percentage of white cells | GCST90002389 | 7.66 |
| 2217 | ITGAV levels | GCST90469639 | 7.65 |
| 2218 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502168 | 7.64 |
| 2219 | CRTAM/GZMA ratio | GCST90314275 | 7.64 |
| 2220 | Other disorders of stomach and duodenum (PheCode 537) | GCST90476054 | 7.63 |
| 2221 | LGALS8/VWF ratio | GCST90315322 | 7.62 |
| 2222 | PGD levels | GCST90470217 | 7.62 |
| 2223 | CEP43/WASF1 ratio | GCST90314023 | 7.61 |
| 2224 | Fractured/broken bones in last 5 years | Medical conditions | UKBB00000258 | 7.60 |
| 2225 | EXTL1 levels | GCST90469161 | 7.60 |
| 2226 | CD84/GP1BA ratio | GCST90313913 | 7.59 |
| 2227 | ERP44/SUMF2 ratio | GCST90314710 | 7.59 |
| 2228 | EFHD1 levels | GCST90469079 | 7.58 |
| 2229 | RGMB/TNFRSF21 ratio | GCST90315772 | 7.58 |
| 2230 | CD2AP/USP8 ratio | GCST90313784 | 7.57 |
| 2231 | aseg rh volume CerebralWhiteMatter | GCST90002632 | 7.56 |
| 2232 | Osteoporosis NOS (PheCode 743.11) | GCST90476260 | 7.56 |
| 2233 | Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606) | GCST90269703 | 7.56 |
| 2234 | CTSH levels | GCST90468913 | 7.56 |
| 2235 | CLEC3B levels | GCST90468770 | 7.55 |
| 2236 | HPCAL1/NUDC ratio | GCST90315074 | 7.55 |
| 2237 | ENO3 levels | GCST90469111 | 7.54 |
| 2238 | PODXL2/SEZ6L ratio | GCST90315702 | 7.53 |
| 2239 | CD58/IL10RB ratio | GCST90313850 | 7.52 |
| 2240 | CD40/ITGB5 ratio | GCST90313816 | 7.51 |
| 2241 | Medication use (immunosuppressants) | GCST90018771 | 7.51 |
| 2242 | DAG1/PDGFA ratio | GCST90314378 | 7.51 |
| 2243 | PON3 levels | GCST90470287 | 7.51 |
| 2244 | Acute peritonitis | FING00000028 | 7.49 |
| 2245 | NXF1 levels | GCST90242149 | 7.49 |
| 2246 | Cholesteryl Esters to Total Lipids in Medium VLDL percentage | GCST90498956 | 7.47 |
| 2247 | NUDT5/TXNRD1 ratio | GCST90315582 | 7.47 |
| 2248 | SDC4/WWP2 ratio | GCST90315821 | 7.47 |
| 2249 | Gamma-CEHC levels | GCST90199864 | 7.46 |
| 2250 | LAT/VASH1 ratio | GCST90315289 | 7.45 |
| 2251 | aseg rh volume Cerebellum-White-Matter | GCST90002635 | 7.45 |
| 2252 | CD69/NFATC1 ratio | GCST90313879 | 7.45 |
| 2253 | ICA1/YTHDF3 ratio | GCST90315113 | 7.45 |
| 2254 | Treatment or medication use - ezetimibe (UKB data field 20003_1141192736) | GCST90042541 | 7.44 |
| 2255 | CDKN1A/DAB2 ratio | GCST90313967 | 7.44 |
| 2256 | Principal component-derived dietary pattern 58 | GCST90133061 | 7.44 |
| 2257 | Free cholesterol in large VLDL | GCST90498181 | 7.44 |
| 2258 | EDAR/IPCEF1 ratio | GCST90314578 | 7.44 |
| 2259 | CLEC1B/GP1BA ratio | GCST90314091 | 7.44 |
| 2260 | Cholesteryl ester (16:2) levels | GCST90024628 | 7.44 |
| 2261 | APP/HBEGF ratio | GCST90313324 | 7.44 |
| 2262 | Total cholesterol levels | GCST90018754 | 7.43 |
| 2263 | FABP2/RBP2 ratio | GCST90314757 | 7.43 |
| 2264 | DAB2/VASH1 ratio | GCST90314369 | 7.42 |
| 2265 | Sphingomyelins levels | GCST90499972 | 7.42 |
| 2266 | MESD/NCK2 ratio | GCST90315421 | 7.41 |
| 2267 | CEP43/USP8 ratio | GCST90314022 | 7.41 |
| 2268 | TBCB/TBCC ratio | GCST90315909 | 7.41 |
| 2269 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 7.41 |
| 2270 | CXCL17/LAMP3 ratio | GCST90314340 | 7.40 |
| 2271 | Omega-6 fatty acids to total fatty acids percentage | GCST90502545 | 7.39 |
| 2272 | Radiculopathy | FING00001238 | 7.39 |
| 2273 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 7.39 |
| 2274 | CEP170 levels | GCST90468711 | 7.39 |
| 2275 | CREG1/SMPDL3A ratio | GCST90314252 | 7.39 |
| 2276 | 1-ribosyl-imidazoleacetate levels | GCST90199815 | 7.39 |
| 2277 | Gout, unspecified | FING00000589 | 7.39 |
| 2278 | EGFL7 levels | GCST90469083 | 7.38 |
| 2279 | F2R/SERPINE1 ratio | GCST90314735 | 7.38 |
| 2280 | Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitor | UKBB00000694 | 7.38 |
| 2281 | Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitor | UKBB00000706 | 7.38 |
| 2282 | Sleep apnea | neurological | UKBB00000774 | 7.37 |
| 2283 | Concentration of IDL particles | GCST90497606 | 7.37 |
| 2284 | Other haemoglobinopathies | FING00001053 | 7.36 |
| 2285 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T223 | ECGA000223 | 7.36 |
| 2286 | Coffee max liking | GCST90094739 | 7.36 |
| 2287 | Omega-3 fatty acid levels | GCST90502055 | 7.36 |
| 2288 | CD40/TNFRSF14 ratio | GCST90313830 | 7.35 |
| 2289 | Plateletcrit | GCST90002400 | 7.34 |
| 2290 | HMOX2/TDRKH ratio | GCST90315067 | 7.34 |
| 2291 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502633 | 7.34 |
| 2292 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499194 | 7.33 |
| 2293 | IDP dMRI ProbtrackX ICVF cst r | GCST90004384 | 7.32 |
| 2294 | IDP dMRI ProbtrackX L2 ifo r | GCST90004286 | 7.32 |
| 2295 | Triglycerides in LDL (UKB data field 23409) | GCST90269506 | 7.32 |
| 2296 | HBEGF levels | GCST90469433 | 7.32 |
| 2297 | DSG2 levels | GCST90427825 | 7.31 |
| 2298 | Linoleic acid levels | GCST90502306 | 7.31 |
| 2299 | Volume of left central nucleus | GCST90474961 | 7.30 |
| 2300 | CLIP2/LAT2 ratio | GCST90314128 | 7.30 |
| 2301 | PEAR1 levels | GCST90470204 | 7.29 |
| 2302 | AMBP/RARRES2 ratio | GCST90313256 | 7.29 |
| 2303 | CDCP1/IL18BP ratio | GCST90313937 | 7.29 |
| 2304 | Bone marrow fat fraction of thoracic vertebra 9 | GCST90652381 | 7.29 |
| 2305 | Cholesteryl Esters to Total Lipids in Large VLDL percentage | GCST90498165 | 7.29 |
| 2306 | LAT/LYN ratio | GCST90315283 | 7.28 |
| 2307 | Ptosis of eyelid | FING00001227 | 7.27 |
| 2308 | Idiopathic gout | FING00000658 | 7.27 |
| 2309 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 7.27 |
| 2310 | Ceramide (d18:1/24:0) levels | GCST90024046 | 7.26 |
| 2311 | Fracture of upper limb (PheCode 803) | GCST90476279 | 7.26 |
| 2312 | QC T1 inverse SNR | GCST90006348 | 7.25 |
| 2313 | Omega-3 fatty acid levels | GCST90502436 | 7.25 |
| 2314 | CD79B/FCRL1 ratio | GCST90313899 | 7.24 |
| 2315 | Liver volume | GCST90566818 | 7.23 |
| 2316 | HNRNPK/VASH1 ratio | GCST90315071 | 7.22 |
| 2317 | ACY1 levels | GCST90468212 | 7.22 |
| 2318 | CCL4 levels | GCST90468583 | 7.21 |
| 2319 | Omega-3 fatty acid levels | GCST90502422 | 7.21 |
| 2320 | BTN2A1/LILRB4 ratio | GCST90313546 | 7.21 |
| 2321 | CPM/LAMP2 ratio | GCST90314215 | 7.21 |
| 2322 | LAYN/TNFRSF4 ratio | GCST90315291 | 7.20 |
| 2323 | TINAGL1 levels | GCST90470873 | 7.20 |
| 2324 | MYH9 levels | GCST90469975 | 7.20 |
| 2325 | Volume of right medial nucleus | GCST90475042 | 7.19 |
| 2326 | Glycosyl ceramide (d18:2/24:1, d18:1/24:2) levels | GCST90200118 | 7.19 |
| 2327 | BCAT1 levels | GCST90468427 | 7.19 |
| 2328 | PDGFA/SCARF1 ratio | GCST90315617 | 7.19 |
| 2329 | ENO2/ITGB1BP2 ratio | GCST90314661 | 7.17 |
| 2330 | Left-hemisphere visual network to left-hemisphere somatomotor network white-matter structural connectivity | GCST90302649 | 7.17 |
| 2331 | Triglycerides in medium HDL (UKB data field 23571) | GCST90269668 | 7.16 |
| 2332 | CD99/PIK3IP1 ratio | GCST90313929 | 7.16 |
| 2333 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 74) | GCST90320637 | 7.16 |
| 2334 | DNAJB1/SIRT2 ratio | GCST90314511 | 7.16 |
| 2335 | Concentration of medium VLDL particles (UKB data field 23502) | GCST90269599 | 7.15 |
| 2336 | Volume of left medial nucleus | GCST90474976 | 7.15 |
| 2337 | SERPINE1 levels | GCST90470596 | 7.15 |
| 2338 | Degree of unsaturation | GCST90502225 | 7.14 |
| 2339 | Principal component-derived dietary pattern 28 | GCST90133033 | 7.14 |
| 2340 | CCL17/GRK5 ratio | GCST90313687 | 7.14 |
| 2341 | COMP/THBS4 ratio | GCST90314193 | 7.12 |
| 2342 | total cholesterol (mean, inv-norm transformed) | GCST90476424 | 7.12 |
| 2343 | Lupus erythematosus | FING00000739 | 7.12 |
| 2344 | GALNT2 levels | GCST90469296 | 7.12 |
| 2345 | CLEC4D levels | GCST90468773 | 7.11 |
| 2346 | PODXL2 levels | GCST90470279 | 7.11 |
| 2347 | CD302 levels | GCST90468624 | 7.10 |
| 2348 | Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641) | GCST90269738 | 7.10 |
| 2349 | F11R/SORT1 ratio | GCST90314726 | 7.10 |
| 2350 | APP/PPP1R12A ratio | GCST90313330 | 7.10 |
| 2351 | Total fatty acid levels | GCST90502722 | 7.10 |
| 2352 | Omega-6 fatty acids to total fatty acids percentage | GCST90502528 | 7.10 |
| 2353 | Free cholesterol in small LDL | GCST90499617 | 7.09 |
| 2354 | Saturated fatty acids levels | GCST90502675 | 7.09 |
| 2355 | Degree of unsaturation | GCST90502737 | 7.08 |
| 2356 | Noninfectious disorders of lymphatic channels (PheCode 450) | GCST90476002 | 7.08 |
| 2357 | CA2/NSFL1C ratio | GCST90313580 | 7.08 |
| 2358 | ARHGAP1/SPARC ratio | GCST90313344 | 7.08 |
| 2359 | Monounsaturated fatty acid levels | GCST90502036 | 7.08 |
| 2360 | Triglyceride levels | GCST90278645 | 7.07 |
| 2361 | RETN levels | GCST90012034 | 7.06 |
| 2362 | MAPRE3 levels | GCST90469859 | 7.05 |
| 2363 | Average diameter for LDL particles | GCST90498457 | 7.04 |
| 2364 | Cholesterol in Small HDL | GCST90499348 | 7.03 |
| 2365 | Myocardial infarction | GCST90018657 | 7.03 |
| 2366 | APRT/EREG ratio | GCST90313335 | 7.02 |
| 2367 | MGLL/PTPN6 ratio | GCST90315440 | 7.02 |
| 2368 | ENPP6 levels | GCST90469117 | 7.02 |
| 2369 | Cardiac defibrillator in situ (PheCode 426.92) | GCST90475961 | 7.02 |
| 2370 | Frailty (Factor 5 - Poorer Cognition) | GCST90624051 | 7.01 |
| 2371 | CIAPIN1/SPARC ratio | GCST90314069 | 7.01 |
| 2372 | Cholesterol to total lipids ratio in large VLDL | GCST90092869 | 7.00 |
| 2373 | HAVCR2 levels | GCST90469432 | 7.00 |
| 2374 | Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453) | GCST90269550 | 7.00 |
| 2375 | N2-acetyl,N6,N6-dimethyllysine levels | GCST90200697 | 7.00 |
| 2376 | DYNLT1 levels | GCST90469057 | 6.99 |
| 2377 | PIGR levels | GCST90470232 | 6.99 |
| 2378 | Varicose veins of lower extremity, symptomtic (PheCode 454.11) | GCST90476014 | 6.98 |
| 2379 | Microvirga abundance in stool | GCST90032479 | 6.98 |
| 2380 | ITGBL1 levels | GCST90469648 | 6.98 |
| 2381 | Depression | GCST003769 | 6.98 |
| 2382 | KIR3DL1 levels | GCST90469687 | 6.97 |
| 2383 | Lymphocyte percentage of white cells | GCST004632 | 6.97 |
| 2384 | CLEC1B/PPP1R2 ratio | GCST90314101 | 6.97 |
| 2385 | SF3B4 levels | GCST90470609 | 6.97 |
| 2386 | Hippocampal subfield left CA3 volume (body) | GCST90267940 | 6.96 |
| 2387 | KLK14 levels | GCST90469700 | 6.95 |
| 2388 | FUOM levels | GCST90469276 | 6.95 |
| 2389 | DTI TBSS L2 Superior fronto-occipital fasciculus R | GCST90384518 | 6.95 |
| 2390 | LAMP3 levels | GCST90469735 | 6.95 |
| 2391 | EBI3_IL27/VCAM1 ratio | GCST90314572 | 6.95 |
| 2392 | Plasma succinylcarnitine (C4-DC) levels in chronic kidney disease | GCST90265998 | 6.95 |
| 2393 | Free cholesterol to total lipids ratio in medium VLDL | GCST90092921 | 6.94 |
| 2394 | Sphingomyelin_41:0_[M+H]1+ levels | GCST90060386 | 6.94 |
| 2395 | CD40/GLOD4 ratio | GCST90313814 | 6.94 |
| 2396 | HSPG2/PTGDS ratio | GCST90315092 | 6.93 |
| 2397 | Other bacterial diseases | FING00000968 | 6.93 |
| 2398 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502415 | 6.93 |
| 2399 | LAT/PLXNA4 ratio | GCST90315286 | 6.93 |
| 2400 | L1CAM/SEZ6L ratio | GCST90315266 | 6.93 |
| 2401 | GBP2 levels | GCST90469312 | 6.93 |
| 2402 | IPCEF1/SPARC ratio | GCST90315186 | 6.93 |
| 2403 | Neuroendocrine tumor and carcinoma of pancreas, excluding all cancers (controls excluding all cancers) | FING00000864 | 6.92 |
| 2404 | C-reactive protein levels (CRP.4337.49.2) | GCST90240503 | 6.92 |
| 2405 | CLEC1B levels | GCST90468768 | 6.91 |
| 2406 | Cholesterol to total lipids ratio in very large HDL | GCST90093005 | 6.91 |
| 2407 | TSPAN1 levels | GCST90470978 | 6.91 |
| 2408 | EDAR/LAT2 ratio | GCST90314582 | 6.91 |
| 2409 | FGFBP1 levels | GCST90469230 | 6.91 |
| 2410 | Hippocampal right GC-ML-DG volume (head) | GCST90267968 | 6.90 |
| 2411 | aseg rh intensity Accumbens-area | GCST90003788 | 6.89 |
| 2412 | EGFLAM levels | GCST90469084 | 6.89 |
| 2413 | ATOX1 levels | GCST90468385 | 6.88 |
| 2414 | Prevotella sp000434975 abundance in stool | GCST90032518 | 6.88 |
| 2415 | F-fatty/dairy food liking (derived food-liking factor) | GCST90094760 | 6.87 |
| 2416 | Cholelithiasis | GCST90018599 | 6.86 |
| 2417 | TNF/TNFRSF1B ratio | GCST90315942 | 6.86 |
| 2418 | Cholesteryl esters to total lipids ratio in small VLDL | GCST90092971 | 6.85 |
| 2419 | LSP1 levels | GCST90469811 | 6.85 |
| 2420 | CNTN4 levels | GCST90468806 | 6.85 |
| 2421 | ACVRL1/TNFRSF19 ratio | GCST90313159 | 6.85 |
| 2422 | ERBIN/SIRT2 ratio | GCST90314696 | 6.84 |
| 2423 | TFPI2 levels | GCST90470838 | 6.84 |
| 2424 | Rosacea (PheCode 695.3) | GCST90476178 | 6.83 |
| 2425 | CD99L2/CPM ratio | GCST90313925 | 6.83 |
| 2426 | IL18BP/THBD ratio | GCST90315156 | 6.82 |
| 2427 | Diastolic blood pressure x sex interaction | GCST90335175 | 6.81 |
| 2428 | Alcohol use disorder, Swedish definition | FING00000053 | 6.81 |
| 2429 | Myo-inositol levels | GCST90243527 | 6.80 |
| 2430 | CD69/CLEC1B ratio | GCST90313869 | 6.79 |
| 2431 | Plasma pregnenetriol sulfate* levels in chronic kidney disease | GCST90265866 | 6.79 |
| 2432 | Acetate levels | GCST90092803 | 6.79 |
| 2433 | Cholesterol levels in very small VLDL | GCST90500712 | 6.78 |
| 2434 | NPY levels | GCST90470081 | 6.78 |
| 2435 | wg rh intensity-contrast superiortemporal | GCST90003856 | 6.77 |
| 2436 | FLI1 levels | GCST90469247 | 6.77 |
| 2437 | CEACAM6 levels | GCST90468697 | 6.76 |
| 2438 | PDGFA levels | GCST90470188 | 6.76 |
| 2439 | COL6A3/SMOC2 ratio | GCST90314178 | 6.76 |
| 2440 | Ovarian dysfunction | FING00001133 | 6.76 |
| 2441 | MAP2K6/TBL1X ratio | GCST90315378 | 6.74 |
| 2442 | IDP dMRI TBSS ICVF Superior cerebellar peduncle R | GCST90004339 | 6.72 |
| 2443 | Docosahexaenoic acid levels | GCST90502243 | 6.72 |
| 2444 | NMI levels | GCST90470056 | 6.72 |
| 2445 | TMSB10/TXNRD1 ratio | GCST90315925 | 6.71 |
| 2446 | DPY30 levels | GCST90469037 | 6.71 |
| 2447 | FUCA1 levels | GCST90469275 | 6.71 |
| 2448 | Abdominal and pelvic pain | Symptoms and signs involving the digestive system and abdomen | UKBB00000001 | 6.71 |
| 2449 | Monounsaturated fatty acid levels | GCST90502347 | 6.71 |
| 2450 | Testicular hypofunction (PheCode 257.1) | GCST90475697 | 6.71 |
| 2451 | Recent feelings of foreboding | Anxiety | UKBB00000738 | 6.71 |
| 2452 | MANF/PRDX5 ratio | GCST90315365 | 6.70 |
| 2453 | Disorders of iron metabolism (PheCode 275.1) | GCST90475743 | 6.70 |
| 2454 | F-dairy liking (derived food-liking factor) | GCST90094751 | 6.69 |
| 2455 | CFHR5 levels | GCST90468728 | 6.68 |
| 2456 | Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093041 | 6.67 |
| 2457 | HGFAC levels | GCST90469448 | 6.67 |
| 2458 | GP6/SCARF1 ratio | GCST90314969 | 6.67 |
| 2459 | Triglycerides to total lipids ratio in large VLDL | GCST90092879 | 6.67 |
| 2460 | X-21286 levels | GCST90200562 | 6.67 |
| 2461 | Triglycerides in small LDL | GCST90499722 | 6.66 |
| 2462 | PAG1 levels | GCST90470147 | 6.66 |
| 2463 | DNER levels | GCST90469019 | 6.65 |
| 2464 | Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587) | GCST90269684 | 6.65 |
| 2465 | Epiandrosterone sulfate levels | GCST90199752 | 6.64 |
| 2466 | TIMP3 levels | GCST90470871 | 6.64 |
| 2467 | Docosahexaenoic acid levels | GCST90502254 | 6.64 |
| 2468 | GUSB levels | GCST90469421 | 6.64 |
| 2469 | CCL5 levels | GCST90468584 | 6.64 |
| 2470 | CCN1/DNAJB1 ratio | GCST90313709 | 6.64 |
| 2471 | CCL5/CXCL3 ratio | GCST90313700 | 6.64 |
| 2472 | Omega-3 fatty acid levels | GCST90502441 | 6.63 |
| 2473 | IDP dMRI ProbtrackX L1 unc l | GCST90004271 | 6.63 |
| 2474 | GP1BA/SDC4 ratio | GCST90314957 | 6.63 |
| 2475 | VTA1 levels | GCST90471058 | 6.63 |
| 2476 | Concentration of VLDL particles (UKB data field 23428) | GCST90269525 | 6.61 |
| 2477 | IDP T1 FAST ROIs R putamen | GCST90002552 | 6.59 |
| 2478 | Cholesteryl esters in very large VLDL | GCST90500556 | 6.59 |
| 2479 | Curry liking | GCST90094750 | 6.58 |
| 2480 | VCAN levels | GCST90471032 | 6.58 |
| 2481 | CLEC4G/LGALS4 ratio | GCST90314120 | 6.58 |
| 2482 | TCL1A/TNFRSF13C ratio | GCST90315912 | 6.57 |
| 2483 | AHSP/HMBS ratio | GCST90313217 | 6.57 |
| 2484 | IDP dMRI TBSS FA Posterior thalamic radiation R | GCST90003905 | 6.57 |
| 2485 | Triglyceride levels in large LDL | GCST90092866 | 6.56 |
| 2486 | Cardiorespiratory fitness slope | GCST90093319 | 6.56 |
| 2487 | CASP3/SERPINB9 ratio | GCST90313642 | 6.56 |
| 2488 | aseg lh intensity Accumbens-area | GCST90003774 | 6.54 |
| 2489 | X-11786--methylcysteine levels | GCST90243654 | 6.54 |
| 2490 | Docosahexaenoic acid to total fatty acids percentage | GCST90502284 | 6.54 |
| 2491 | rfMRI amplitudes (ICA100 node 27) | GCST90004615 | 6.54 |
| 2492 | Unspecified dementia | FING00001400 | 6.53 |
| 2493 | Tonsillectomy and adenotomy | FING00001367 | 6.53 |
| 2494 | MYOC/RGMB ratio | GCST90315508 | 6.53 |
| 2495 | ATF6 levels | GCST90240816 | 6.53 |
| 2496 | EIF4B/MAP4K5 ratio | GCST90314623 | 6.52 |
| 2497 | FCRL1 levels | GCST90469205 | 6.52 |
| 2498 | CTSZ levels | GCST90468918 | 6.52 |
| 2499 | P4HB/PPP1R12A ratio | GCST90315591 | 6.52 |
| 2500 | CRISP3 levels | GCST90468866 | 6.52 |
| 2501 | Triglyceride levels in medium HDL | GCST90092902 | 6.52 |
| 2502 | Total cholesterol levels | GCST90278644 | 6.52 |
| 2503 | Free cholesterol to total lipids ratio in medium LDL | GCST90092909 | 6.51 |
| 2504 | MAVS/PPP1R9B ratio | GCST90315393 | 6.51 |
| 2505 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502179 | 6.50 |
| 2506 | PTGR1 levels | GCST90470370 | 6.49 |
| 2507 | ICD10 O42: Premature rupture of membranes | GCST90454238 | 6.48 |
| 2508 | AmygNuclei rh volume Central-nucleus | GCST90002662 | 6.48 |
| 2509 | DBI/MESD ratio | GCST90314409 | 6.48 |
| 2510 | NIT1 levels | GCST90470050 | 6.48 |
| 2511 | NPPC levels | GCST90470075 | 6.47 |
| 2512 | Conductive hearing loss (PheCode 389.2) | GCST90475912 | 6.47 |
| 2513 | CRELD2/TXNDC5 ratio | GCST90314259 | 6.46 |
| 2514 | Linoleic acid to total fatty acids percentage | GCST90502017 | 6.46 |
| 2515 | FOXO1/SNAP23 ratio | GCST90314875 | 6.46 |
| 2516 | ABHD14B/CCS ratio | GCST90313139 | 6.46 |
| 2517 | DDAH1 levels | GCST90468966 | 6.45 |
| 2518 | X-24406 metabolite level | GCST90616789 | 6.45 |
| 2519 | Cholesterol in Medium LDL | GCST90498707 | 6.45 |
| 2520 | White blood cell count (basophil) | GCST004618 | 6.44 |
| 2521 | IFNG levels | GCST90469515 | 6.44 |
| 2522 | IL1RAP levels | GCST90469573 | 6.44 |
| 2523 | CDKN1A/PLA2G4A ratio | GCST90313974 | 6.44 |
| 2524 | IL1B levels | GCST90469570 | 6.42 |
| 2525 | Docosahexaenoic acid levels | GCST90502259 | 6.42 |
| 2526 | ANG/RARRES2 ratio | GCST90313271 | 6.42 |
| 2527 | Non-seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00000874 | 6.42 |
| 2528 | Honey liking | GCST90094782 | 6.42 |
| 2529 | CDKN1A/HBEGF ratio | GCST90313972 | 6.41 |
| 2530 | KDR levels | GCST90469672 | 6.41 |
| 2531 | Cholesteryl Esters in IDL | GCST90497523 | 6.41 |
| 2532 | PCSK9 levels | GCST90470177 | 6.40 |
| 2533 | PZP levels | GCST90470399 | 6.39 |
| 2534 | Platelet crit (UKB data field 30090) | GCST90468096 | 6.39 |
| 2535 | ALCAM/CNTN1 ratio | GCST90313235 | 6.39 |
| 2536 | F-highly palatable foods liking (derived food-liking factor) | GCST90094785 | 6.39 |
| 2537 | EIF3J levels | GCST90241122 | 6.39 |
| 2538 | FUT8/SORT1 ratio | GCST90314892 | 6.38 |
| 2539 | EGFR levels | GCST90469085 | 6.38 |
| 2540 | Triglyceride levels in IDL | GCST90092841 | 6.38 |
| 2541 | SPARCL1 levels | GCST90242870 | 6.37 |
| 2542 | Familial combined hyperlipidemia defined by Brunzell criteria | GCST90104003 | 6.36 |
| 2543 | Mean corpuscular hemoglobin | GCST90002323 | 6.36 |
| 2544 | Concentration of VLDL particles | GCST90093000 | 6.36 |
| 2545 | Prescriptions - sulfonylurea|diabetes | UKBB00000703 | 6.36 |
| 2546 | Chronic sinusitis (PheCode 475) | GCST90476020 | 6.36 |
| 2547 | IDP dMRI ProbtrackX L2 ifo l | GCST90004285 | 6.35 |
| 2548 | Secondary hypothyroidism (PheCode 244.1) | GCST90475649 | 6.35 |
| 2549 | CALCOCO1/CASP3 ratio | GCST90313596 | 6.34 |
| 2550 | T1 CAT volume L VIIIb | GCST90384130 | 6.33 |
| 2551 | HYOU1/RARRES2 ratio | GCST90315103 | 6.33 |
| 2552 | CLEC6A levels | GCST90468777 | 6.33 |
| 2553 | CCL5/LAMA4 ratio | GCST90313703 | 6.33 |
| 2554 | Cholelithiasis | digestive | UKBB00000131 | 6.33 |
| 2555 | COL5A1 levels | GCST90468820 | 6.32 |
| 2556 | C36:4 Phosphatidylethanolamine levels in chronic kidney disease | GCST90257357 | 6.32 |
| 2557 | aseg rh volume Amygdala | GCST90002642 | 6.32 |
| 2558 | CXCL17 levels | GCST90468929 | 6.32 |
| 2559 | PFKFB2/SRP14 ratio | GCST90315650 | 6.32 |
| 2560 | EZR levels | GCST90469162 | 6.32 |
| 2561 | HDGF levels | GCST90469442 | 6.31 |
| 2562 | EPHB6/TNFRSF9 ratio | GCST90314682 | 6.31 |
| 2563 | APOM/ERBB3 ratio | GCST90313314 | 6.30 |
| 2564 | Fractured bone site(s) - Wrist | Medical conditions | UKBB00000257 | 6.30 |
| 2565 | BIN2/EREG ratio | GCST90313503 | 6.30 |
| 2566 | aparc-a2009s rh volume S-oc-middle+Lunatus | GCST90003055 | 6.30 |
| 2567 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 6.29 |
| 2568 | CCN2/EDAR ratio | GCST90313711 | 6.29 |
| 2569 | PHYKPL levels | GCST90470228 | 6.29 |
| 2570 | MITD1/WWP2 ratio | GCST90315458 | 6.29 |
| 2571 | ATRN levels | GCST90468400 | 6.28 |
| 2572 | Phosphatidylethanolamine (18:0_18:1) levels | GCST90024977 | 6.28 |
| 2573 | Allergic conjunctivitis | FING00000067 | 6.28 |
| 2574 | CERT levels | GCST90468717 | 6.28 |
| 2575 | Phospholipids to total lipids in large VLDL percentage (UKB data field 23589) | GCST90269686 | 6.26 |
| 2576 | Alkylphosphatidylcholine (O-34:1) levels | GCST90024925 | 6.26 |
| 2577 | C8 Carnitine levels in chronic kidney disease | GCST90257680 | 6.26 |
| 2578 | SSC5D levels | GCST90470748 | 6.25 |
| 2579 | total cholesterol (minimum, inv-norm transformed) | GCST90476427 | 6.25 |
| 2580 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T229 | ECGU000229 | 6.25 |
| 2581 | Sleep disorders | neurological | UKBB00000776 | 6.25 |
| 2582 | Plasma 4-guanidinobutanoate levels in chronic kidney disease | GCST90264620 | 6.24 |
| 2583 | GDNF levels | GCST90469323 | 6.24 |
| 2584 | CDKN1A/ENO2 ratio | GCST90313969 | 6.24 |
| 2585 | PMVK levels | GCST90470272 | 6.24 |
| 2586 | DTI TBSS L2 Superior cerebellar peduncle R | GCST90384488 | 6.24 |
| 2587 | F2R/ITGB1BP2 ratio | GCST90314731 | 6.23 |
| 2588 | Saturated fatty acids levels | GCST90502674 | 6.23 |
| 2589 | KLK6 levels | GCST90469705 | 6.22 |
| 2590 | TTR levels | GCST90470985 | 6.22 |
| 2591 | BSG/IL12A_IL12B ratio | GCST90313532 | 6.21 |
| 2592 | Milk type used - Full cream | Diet | UKBB00000468 | 6.21 |
| 2593 | CD69/SCARF1 ratio | GCST90313885 | 6.21 |
| 2594 | RAB6A levels | GCST90470412 | 6.19 |
| 2595 | DKK1/SERPINE1 ratio | GCST90314480 | 6.18 |
| 2596 | Omega-3 fatty acid levels | GCST90502064 | 6.18 |
| 2597 | wg lh intensity-contrast lateralorbitofrontal | GCST90003803 | 6.18 |
| 2598 | Omega-6 fatty acids levels | GCST90499177 | 6.18 |
| 2599 | Other and unspecified tonsillitis | FING00000954 | 6.18 |
| 2600 | CA1/CA3 ratio | GCST90313572 | 6.17 |
| 2601 | HBEGF/PDGFA ratio | GCST90315033 | 6.17 |
| 2602 | Cholesterol to total lipids in small LDL percentage (UKB data field 23625) | GCST90269722 | 6.17 |
| 2603 | Synovitis and tenosynovitis (PheCode 727.1) | GCST90476242 | 6.17 |
| 2604 | CD74 levels | GCST90468647 | 6.16 |
| 2605 | PRELP levels | GCST90470321 | 6.16 |
| 2606 | EDAR/SDC4 ratio | GCST90314585 | 6.16 |
| 2607 | IDP dMRI TBSS L1 Retrolenticular part of internal capsule L | GCST90004096 | 6.16 |
| 2608 | SNX18 levels | GCST90470700 | 6.16 |
| 2609 | CILP levels | GCST90468754 | 6.15 |
| 2610 | HCLS1 levels | GCST90469437 | 6.14 |
| 2611 | ATOX1/TMSB10 ratio | GCST90313377 | 6.14 |
| 2612 | Free cholesterol in small HDL | GCST90499411 | 6.14 |
| 2613 | SOST levels | GCST90470711 | 6.14 |
| 2614 | HAVCR1 levels | GCST90469431 | 6.14 |
| 2615 | CRELD1 levels | GCST90468858 | 6.13 |
| 2616 | PDGFB/PRKAR1A ratio | GCST90315624 | 6.13 |
| 2617 | Acetone levels | GCST90092805 | 6.13 |
| 2618 | GFER/TRIAP1 ratio | GCST90314921 | 6.12 |
| 2619 | Bone marrow fat fraction of thoracic vertebra 11 | GCST90652383 | 6.12 |
| 2620 | Cholesterol to total lipids ratio in medium LDL | GCST90092905 | 6.12 |
| 2621 | Linoleic acid levels | GCST90502010 | 6.11 |
| 2622 | T1 CAT volume L IX | GCST90384133 | 6.11 |
| 2623 | IDP dMRI TBSS MO Medial lemniscus R | GCST90003960 | 6.11 |
| 2624 | KIFBP/LYN ratio | GCST90315246 | 6.11 |
| 2625 | NSFL1C/RILP ratio | GCST90315560 | 6.10 |
| 2626 | CD274 levels | GCST90468613 | 6.10 |
| 2627 | Loneliness (standard GWA) | GCST90267288 | 6.09 |
| 2628 | Triglycerides to total lipids ratio in IDL | GCST90092842 | 6.08 |
| 2629 | IDP dMRI ProbtrackX L3 cst l | GCST90004308 | 6.07 |
| 2630 | CLEC4C levels | GCST90468772 | 6.07 |
| 2631 | FSTL1 levels | GCST90469271 | 6.07 |
| 2632 | Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608) | GCST90269705 | 6.07 |
| 2633 | IDP dMRI TBSS MD Sagittal stratum L | GCST90004058 | 6.07 |
| 2634 | FCRL1/TCL1A ratio | GCST90314795 | 6.06 |
| 2635 | Concentration of medium VLDL particles | GCST90092923 | 6.06 |
| 2636 | FCER2 levels | GCST90469199 | 6.06 |
| 2637 | ADAM23 levels | GCST90240922 | 6.05 |
| 2638 | S100A11 levels | GCST90470512 | 6.05 |
| 2639 | BCR/NFATC1 ratio | GCST90313496 | 6.05 |
| 2640 | Small cell lung carcinoma | GCST004746 | 6.05 |
| 2641 | Percentage of M9 (GP18) | GCST90668462 | 6.04 |
| 2642 | OSCAR levels | GCST90470131 | 6.04 |
| 2643 | SERPINA3 levels | GCST90470583 | 6.04 |
| 2644 | Loneliness (weighted GWA) | GCST90267289 | 6.04 |
| 2645 | CD58/TYRO3 ratio | GCST90313856 | 6.03 |
| 2646 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 6.03 |
| 2647 | Chronic obstructive pulmonary disease in never smokers | GCST90016589 | 6.02 |
| 2648 | Plasma 11beta-hydroxyandrosterone glucuronide levels in chronic kidney disease | GCST90264321 | 6.02 |
| 2649 | Lignoceroylcarnitine (C24) levels | GCST90200137 | 6.02 |
| 2650 | C2 levels | GCST90468497 | 6.02 |
| 2651 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 6.01 |
| 2652 | Saturated fatty acids levels | GCST90502192 | 6.01 |
| 2653 | Omega-6 fatty acid levels | GCST90502514 | 6.01 |
| 2654 | wg rh intensity-contrast fusiform | GCST90003833 | 6.00 |
| 2655 | Burger liking | GCST90094715 | 6.00 |
| 2656 | Mean platelet volume at delivery | GCST90302232 | 5.99 |
| 2657 | Interpolated Age of participant when operation took place | Operations | UKBB00000370 | 5.99 |
| 2658 | CD19 on IgD- CD38- B cell | GCST90001733 | 5.99 |
| 2659 | Total fatty acid levels | GCST90502218 | 5.99 |
| 2660 | IDP dMRI TBSS MD Pontine crossing tract | GCST90004028 | 5.99 |
| 2661 | SERPINI1 levels | GCST90470602 | 5.99 |
| 2662 | Operative procedures - Total cholecystectomy NEC | Summary Operations | UKBB00000589 | 5.98 |
| 2663 | IL16/NADK ratio | GCST90315152 | 5.97 |
| 2664 | ECM1 levels | GCST90469065 | 5.97 |
| 2665 | CXCL16 levels | GCST90240524 | 5.96 |
| 2666 | MAX levels | GCST90469867 | 5.96 |
| 2667 | Physical activity (Total log acceleration 8pm-10pm) | GCST90061419 | 5.96 |
| 2668 | FYB1/MESD ratio | GCST90314911 | 5.96 |
| 2669 | Primary biliary cholangitis (PBC) | FING00001211 | 5.96 |
| 2670 | SH3BP1 levels | GCST90470619 | 5.95 |
| 2671 | DNAJB1/METAP2 ratio | GCST90314509 | 5.95 |
| 2672 | Physical activity | GCST90093322 | 5.95 |
| 2673 | CC2D1A/TMSB10 ratio | GCST90313667 | 5.95 |
| 2674 | Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605) | GCST90269702 | 5.94 |
| 2675 | ENO2/PRSS27 ratio | GCST90314666 | 5.94 |
| 2676 | Acetate levels (UKB data field 23475) | GCST90269572 | 5.94 |
| 2677 | Migraine | GCST90468142 | 5.93 |
| 2678 | Alzheimer's disease (MTAG) | GCST90449055 | 5.93 |
| 2679 | Gouty arthropathy (PheCode 274.11) | GCST90475738 | 5.93 |
| 2680 | SIGLEC1/SSC5D ratio | GCST90315844 | 5.93 |
| 2681 | Lysoalkylphosphatidylcholine (O-24:2) levels | GCST90025438 | 5.93 |
| 2682 | MEGF10 levels | GCST90469882 | 5.93 |
| 2683 | Alkenylphosphatidylethanolamine (P-20:0/18:2) levels | GCST90025683 | 5.92 |
| 2684 | ITGB7 levels | GCST90469647 | 5.91 |
| 2685 | Mean platelet volume during the postpartum period | GCST90302233 | 5.91 |
| 2686 | Low density lipoprotein cholesterol levels | GCST90002412 | 5.90 |
| 2687 | Alkylphosphatidylcholine (O-16:0/16:0) levels | GCST90024913 | 5.90 |
| 2688 | Phospholipid levels in very large HDL | GCST90132642 | 5.90 |
| 2689 | Alkenylphosphatidylcholine (P-36:3) levels | GCST90024954 | 5.90 |
| 2690 | Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452) | GCST90269549 | 5.89 |
| 2691 | ALB/Globulin ratio | UKBB00000020 | 5.89 |
| 2692 | Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels | GCST90060423 | 5.89 |
| 2693 | Free cholesterol to total lipids ratio in large VLDL | GCST90092873 | 5.88 |
| 2694 | Verbal-numerical reasoning | GCST003498 | 5.88 |
| 2695 | SUSD5 levels | GCST90470789 | 5.88 |
| 2696 | Clinical anxiety and depression (confirmatory factor analysis Factor 3) | GCST90309338 | 5.88 |
| 2697 | CASP3/MESD ratio | GCST90313636 | 5.87 |
| 2698 | TOP2B levels | GCST90470934 | 5.87 |
| 2699 | FYB1/PDGFB ratio | GCST90314912 | 5.86 |
| 2700 | AIFM1 levels | GCST90468268 | 5.86 |
| 2701 | Pain type(s) experienced in last month - Neck or shoulder pain | Pain | UKBB00000630 | 5.85 |
| 2702 | ADAMTS4 levels | GCST90468226 | 5.85 |
| 2703 | GGH levels | GCST90469335 | 5.85 |
| 2704 | Total Ceramide levels | GCST90024578 | 5.84 |
| 2705 | aparc-DKTatlas rh volume parsopercularis | GCST90002909 | 5.83 |
| 2706 | SEMA4D levels | GCST90470573 | 5.83 |
| 2707 | Docosahexaenoic acid levels | GCST90502258 | 5.83 |
| 2708 | HSPB1/PLIN3 ratio | GCST90315088 | 5.82 |
| 2709 | 21-hydroxypregnenolone disulfate levels | GCST90199849 | 5.82 |
| 2710 | IDP T1 FAST ROIs V cerebellum X | GCST90002588 | 5.82 |
| 2711 | RARRES2/ST6GAL1 ratio | GCST90315759 | 5.82 |
| 2712 | PLAU/PLAUR ratio | GCST90315674 | 5.81 |
| 2713 | NOTCH3 levels | GCST90470067 | 5.81 |
| 2714 | MFAP5 levels | GCST90469899 | 5.81 |
| 2715 | Prevotellamassilia abundance in stool | GCST90032517 | 5.80 |
| 2716 | Osteoporosis (PheCode 743.1) | GCST90476259 | 5.80 |
| 2717 | EDAR/SPARC ratio | GCST90314588 | 5.79 |
| 2718 | AGRP levels | GCST90240217 | 5.79 |
| 2719 | F2R/MPIG6B ratio | GCST90314732 | 5.79 |
| 2720 | DAG1/HBEGF ratio | GCST90314376 | 5.77 |
| 2721 | Cholesterol levels in very large VLDL | GCST90500517 | 5.77 |
| 2722 | Sleep disorders | Episodic and paroxysmal disorders | UKBB00000775 | 5.76 |
| 2723 | XRCC4 levels | GCST90471085 | 5.76 |
| 2724 | IL12RB1 levels | GCST90469550 | 5.76 |
| 2725 | CNTNAP2 levels | GCST90468808 | 5.75 |
| 2726 | GSTA3/KRT18 ratio | GCST90314997 | 5.74 |
| 2727 | PPP1R12A/SPARC ratio | GCST90315712 | 5.74 |
| 2728 | F-healthy food liking (derived food-liking factor) | GCST90094779 | 5.74 |
| 2729 | PLB1 levels | GCST90470253 | 5.74 |
| 2730 | Omega-6 fatty acids to total fatty acids percentage | GCST90502540 | 5.74 |
| 2731 | B4GALT1/SMOC2 ratio | GCST90313433 | 5.73 |
| 2732 | ECG, heart rate | ECG during exercise | UKBB00000204 | 5.73 |
| 2733 | IDP T1 FAST ROIs L cerebellum crus II | GCST90002572 | 5.73 |
| 2734 | DKK1/SDC4 ratio | GCST90314479 | 5.72 |
| 2735 | CDKN1A levels | GCST90468684 | 5.72 |
| 2736 | TMSB10/TRIAP1 ratio | GCST90315924 | 5.72 |
| 2737 | total cholesterol (maximum, inv-norm transformed) | GCST90476420 | 5.72 |
| 2738 | MPIG6B/PLXNA4 ratio | GCST90315483 | 5.71 |
| 2739 | ANXA1 levels | GCST90240296 | 5.70 |
| 2740 | Main speciality of consultant (recoded) - Gastroenterology | Summary Administration | UKBB00000415 | 5.69 |
| 2741 | ESYT2 levels | GCST90469156 | 5.69 |
| 2742 | CD74/DLL1 ratio | GCST90313891 | 5.68 |
| 2743 | RASSF2 levels | GCST90470431 | 5.68 |
| 2744 | Chronic ulcer of skin (PheCode 707) | GCST90476216 | 5.68 |
| 2745 | Platelet distribution width (UKB data field 30110) | GCST90468097 | 5.68 |
| 2746 | HMCN2 levels | GCST90469461 | 5.68 |
| 2747 | Mean platelet volume | GCST004599 | 5.67 |
| 2748 | IDP dMRI TBSS L3 Cingulum hippocampus L | GCST90004208 | 5.67 |
| 2749 | LY75 levels | GCST90469822 | 5.67 |
| 2750 | ADAMTS8/FAP ratio | GCST90313172 | 5.66 |
| 2751 | NOTCH1/SEMA7A ratio | GCST90315545 | 5.66 |
| 2752 | CST6/GAL ratio | GCST90314302 | 5.66 |
| 2753 | Birth weight known - No | Early life factors | UKBB00000096 | 5.66 |
| 2754 | Omega-3 fatty acids to total fatty acids percentage | GCST90502082 | 5.65 |
| 2755 | SNX2 levels | GCST90470701 | 5.65 |
| 2756 | ACE2 levels | GCST90468197 | 5.65 |
| 2757 | CD74/IL18BP ratio | GCST90313892 | 5.64 |
| 2758 | Glycated haemoglobin (HbA1c) | Blood biochemistry | UKBB00000289 | 5.63 |
| 2759 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502077 | 5.63 |
| 2760 | DLL1/IL18BP ratio | GCST90314495 | 5.63 |
| 2761 | Saturated fatty acids to total fatty acids percentage | GCST90502207 | 5.63 |
| 2762 | FKBP5/TBCC ratio | GCST90314849 | 5.63 |
| 2763 | Glycosyl ceramide (d18:1/20:0, d16:1/22:0) levels | GCST90200145 | 5.62 |
| 2764 | CXCL5/EDAR ratio | GCST90314349 | 5.62 |
| 2765 | Cholesteryl esters to total lipids in medium LDL percentage (UKB data field 23621) | GCST90269718 | 5.62 |
| 2766 | CASP8/PRDX6 ratio | GCST90313655 | 5.61 |
| 2767 | FCRL1/TNFRSF13C ratio | GCST90314796 | 5.61 |
| 2768 | Bone marrow fat fraction of lumbar vertebra 1 | GCST90652386 | 5.61 |
| 2769 | ADAMTS15 levels | GCST90468223 | 5.60 |
| 2770 | SLAMF7/TXNDC15 ratio | GCST90315850 | 5.60 |
| 2771 | Volume of right cortical nucleus | GCST90475030 | 5.60 |
| 2772 | Percentage of trisyalated structures in total plasma glycans (GP97) | GCST90668541 | 5.59 |
| 2773 | CNST levels | GCST90468801 | 5.59 |
| 2774 | MAP4K5/TBCC ratio | GCST90315385 | 5.59 |
| 2775 | Sulcal opening distance of the right calloso-marginal posterior fissure | GCST90104946 | 5.58 |
| 2776 | Chronic obstructive pulmonary disease x ever smoker interaction (main effect) | GCST90016586 | 5.57 |
| 2777 | Platelet count | GCST004603 | 5.57 |
| 2778 | Left eye overall retinal pigment epithelium thickness | GCST90672032 | 5.57 |
| 2779 | Omega-3 fatty acids to total fatty acids percentage | GCST90502090 | 5.56 |
| 2780 | CTBS levels | GCST90468900 | 5.56 |
| 2781 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 47) | GCST90320610 | 5.56 |
| 2782 | IDP dMRI ProbtrackX FA ptr r | GCST90003945 | 5.56 |
| 2783 | GZMA levels | GCST90469423 | 5.56 |
| 2784 | Omega-3 fatty acids to total fatty acids percentage | GCST90502467 | 5.55 |
| 2785 | AZU1/CEACAM8 ratio | GCST90313424 | 5.55 |
| 2786 | LTBP2/MYOC ratio | GCST90315337 | 5.55 |
| 2787 | SNAP29/TJAP1 ratio | GCST90315861 | 5.54 |
| 2788 | Doctor diagnosed hayfever or allergic rhinitis | Medical information | UKBB00000192 | 5.54 |
| 2789 | Activities undertaken to treat depression | Depression | UKBB00000010 | 5.54 |
| 2790 | CHMP1A/EREG ratio | GCST90314048 | 5.53 |
| 2791 | Number of operations, self-reported | Operations | UKBB00000539 | 5.52 |
| 2792 | Citrate levels | GCST90497200 | 5.51 |
| 2793 | Triacylglycerol_47:4_[M+NH4]1+ levels | GCST90060391 | 5.51 |
| 2794 | DTI TBSS L1 Splenium of corpus callosum | GCST90384432 | 5.51 |
| 2795 | KLK11 levels | GCST90012012 | 5.50 |
| 2796 | CD300LG/CD93 ratio | GCST90313800 | 5.50 |
| 2797 | GZMA/TNFRSF4 ratio | GCST90315013 | 5.50 |
| 2798 | Androstenediol (3beta,17beta) disulfate (1) levels | GCST90199842 | 5.50 |
| 2799 | CD99/KITLG ratio | GCST90313924 | 5.50 |
| 2800 | Inflammatory markers and poor diet (confirmatory factor analysis Factor 30) | GCST90309364 | 5.49 |
| 2801 | Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555) | GCST90476065 | 5.49 |
| 2802 | Cholesteryl Esters in Large VLDL | GCST90498154 | 5.49 |
| 2803 | NINJ1 levels | GCST90470049 | 5.49 |
| 2804 | platelet count (minimum, inv-norm transformed) | GCST90476302 | 5.48 |
| 2805 | MSMB levels | GCST90469949 | 5.48 |
| 2806 | Phospholipids in large HDL | GCST90497853 | 5.47 |
| 2807 | CDH2/SSC4D ratio | GCST90313951 | 5.47 |
| 2808 | Triglycerides in large LDL | GCST90498076 | 5.46 |
| 2809 | PFKFB2 levels | GCST90470215 | 5.46 |
| 2810 | Cholesterol to total lipids ratio in very large VLDL | GCST90093017 | 5.46 |
| 2811 | Basal cell carcinoma | GCST90468114 | 5.45 |
| 2812 | APP/DAG1 ratio | GCST90313320 | 5.45 |
| 2813 | Bifidobacterium kashiwanohense abundance in stool | GCST90032226 | 5.45 |
| 2814 | Primary sclerosing cholangitis | GCST004030 | 5.44 |
| 2815 | DTI TBSS L3 Splenium of corpus callosum | GCST90384528 | 5.44 |
| 2816 | CNST/ITGB1BP2 ratio | GCST90314158 | 5.43 |
| 2817 | IDP dMRI TBSS L3 Posterior thalamic radiation R | GCST90004199 | 5.43 |
| 2818 | EDAR/ITGB1BP2 ratio | GCST90314580 | 5.42 |
| 2819 | DPP10 levels | GCST90469032 | 5.42 |
| 2820 | BIN1 levels | GCST90090757 | 5.42 |
| 2821 | Ever suffered mental distress preventing usual activities | Mental distress | UKBB00000223 | 5.41 |
| 2822 | F-fatty/salty food liking (derived food-liking factor) | GCST90094759 | 5.40 |
| 2823 | DAB2/ERBIN ratio | GCST90314361 | 5.40 |
| 2824 | EDIL3 levels | GCST90469072 | 5.40 |
| 2825 | IDP dMRI TBSS ICVF Posterior corona radiata R | GCST90004353 | 5.40 |
| 2826 | AKR7L levels | GCST90468275 | 5.40 |
| 2827 | Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI) | GCST90267573 | 5.40 |
| 2828 | KEL levels | GCST90469673 | 5.39 |
| 2829 | FURIN/IGSF3 ratio | GCST90314885 | 5.39 |
| 2830 | CXCL11 levels | GCST90468924 | 5.39 |
| 2831 | FCRL2/KLB ratio | GCST90314798 | 5.38 |
| 2832 | NFKB1 levels | GCST90470037 | 5.38 |
| 2833 | Free cholesterol to total lipids ratio in small VLDL | GCST90092973 | 5.38 |
| 2834 | ANXA3/SERPINB1 ratio | GCST90313289 | 5.37 |
| 2835 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 5.37 |
| 2836 | Myasthenia gravis | GCST90093061 | 5.37 |
| 2837 | AK1/PEBP1 ratio | GCST90313225 | 5.37 |
| 2838 | CXCL6 levels | GCST90468933 | 5.37 |
| 2839 | CD200/CLEC4G ratio | GCST90313746 | 5.37 |
| 2840 | TCN2 levels | GCST90470820 | 5.37 |
| 2841 | TFRC levels | GCST90451684 | 5.36 |
| 2842 | IDP dMRI ProbtrackX ICVF fmi | GCST90004386 | 5.36 |
| 2843 | GALNT10/TNFSF12 ratio | GCST90314916 | 5.35 |
| 2844 | NPTXR levels | GCST90470080 | 5.35 |
| 2845 | SCARA3 levels | GCST90427856 | 5.35 |
| 2846 | Saturated fatty acids to total fatty acids percentage | GCST90499958 | 5.35 |
| 2847 | IDP dMRI TBSS L2 Sagittal stratum L | GCST90004154 | 5.35 |
| 2848 | Vitamin and mineral supplements - Multivitamins +/- minerals | Medication | UKBB00000900 | 5.34 |
| 2849 | CA4 levels | GCST90468513 | 5.34 |
| 2850 | HBEGF/YES1 ratio | GCST90315039 | 5.34 |
| 2851 | VAMP8 levels | GCST90471025 | 5.34 |
| 2852 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502645 | 5.33 |
| 2853 | ARHGEF12/DECR1 ratio | GCST90313349 | 5.33 |
| 2854 | SSH3 levels | GCST90470749 | 5.32 |
| 2855 | IDP T1 FIRST left pallidum volume | GCST90002442 | 5.32 |
| 2856 | wg lh intensity-contrast temporalpole | GCST90003824 | 5.31 |
| 2857 | Ribothymidine levels in chronic kidney disease | GCST90257554 | 5.31 |
| 2858 | F-deep fried food liking (derived food-liking factor) | GCST90094753 | 5.31 |
| 2859 | GZMH/KLRD1 ratio | GCST90315016 | 5.30 |
| 2860 | CLIP2/DNAJA2 ratio | GCST90314127 | 5.30 |
| 2861 | Seborrhoeic dermatitis | FING00001282 | 5.30 |
| 2862 | F9/RARRES2 ratio | GCST90314749 | 5.30 |
| 2863 | PDGFB/PPP1R12A ratio | GCST90315623 | 5.30 |
| 2864 | aparc-a2009s rh area S-central | GCST90003415 | 5.30 |
| 2865 | Triglycerides to total lipids ratio in very large VLDL | GCST90093027 | 5.29 |
| 2866 | DTI TBSS MD Sagittal stratum L | GCST90384603 | 5.29 |
| 2867 | CRIM1 levels | GCST90468863 | 5.29 |
| 2868 | Phospholipids to total lipids in medium LDL percentage (UKB data field 23619) | GCST90269716 | 5.29 |
| 2869 | IDP dMRI ProbtrackX L3 fmi | GCST90004311 | 5.29 |
| 2870 | Polyunsaturated fatty acid levels | GCST90502623 | 5.29 |
| 2871 | PKLR/UBAC1 ratio | GCST90315660 | 5.29 |
| 2872 | CA4/PECAM1 ratio | GCST90313586 | 5.29 |
| 2873 | Cholesterol to total lipids ratio in small VLDL | GCST90092969 | 5.29 |
| 2874 | Otitis media (PheCode 381.1) | GCST90475903 | 5.29 |
| 2875 | IL34 levels | GCST90469593 | 5.28 |
| 2876 | BLVRB/CA1 ratio | GCST90313521 | 5.28 |
| 2877 | Maximum indexed left atrial volume | GCST90019012 | 5.28 |
| 2878 | MAVS/TBL1X ratio | GCST90315399 | 5.28 |
| 2879 | Hypercalcemia (PheCode 275.6) | GCST90475748 | 5.27 |
| 2880 | Polyunsaturated fatty acid levels | GCST90499271 | 5.27 |
| 2881 | PRTG levels | GCST90470347 | 5.27 |
| 2882 | TREH levels | GCST90470959 | 5.27 |
| 2883 | PPP1R2/TBL1X ratio | GCST90315720 | 5.27 |
| 2884 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 5.27 |
| 2885 | Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596) | GCST90269693 | 5.27 |
| 2886 | Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622) | GCST90269719 | 5.26 |
| 2887 | Free cholesterol to total lipids ratio in small HDL | GCST90092949 | 5.26 |
| 2888 | CXCL9 levels | GCST90274784 | 5.26 |
| 2889 | EDAR/PSRC1 ratio | GCST90314584 | 5.26 |
| 2890 | IDP dMRI ProbtrackX L1 fmi | GCST90004257 | 5.26 |
| 2891 | Phospholipids to total lipids ratio in very large VLDL | GCST90093025 | 5.25 |
| 2892 | Linoleic acid to total fatty acids percentage | GCST90502332 | 5.25 |
| 2893 | CD38/IL12A_IL12B ratio | GCST90313808 | 5.25 |
| 2894 | AIFM1/PLXNA4 ratio | GCST90313220 | 5.24 |
| 2895 | Acquired hypothyroidism (PheCode 244.2) | GCST90475650 | 5.24 |
| 2896 | Body mass index | GCST90103751 | 5.24 |
| 2897 | wg rh intensity-contrast inferiortemporal | GCST90003835 | 5.24 |
| 2898 | IGF1R levels | GCST90469524 | 5.24 |
| 2899 | PTPRM levels | GCST90470384 | 5.23 |
| 2900 | Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631) | GCST90269728 | 5.23 |
| 2901 | CSF1 levels | GCST90468881 | 5.23 |
| 2902 | DTI TBSS MD Splenium of corpus callosum | GCST90384576 | 5.23 |
| 2903 | ERMAP levels | GCST90469147 | 5.22 |
| 2904 | Total fatty acid levels | GCST90500053 | 5.22 |
| 2905 | VEGFB levels | GCST90471035 | 5.22 |
| 2906 | CC2D1A/STIP1 ratio | GCST90313665 | 5.22 |
| 2907 | IDP dMRI TBSS MO Retrolenticular part of internal capsule R | GCST90003972 | 5.21 |
| 2908 | Low hand grip strength (60 years and older) (FNIH) | GCST90007529 | 5.21 |
| 2909 | F-cheese liking (derived food-liking factor) | GCST90094729 | 5.21 |
| 2910 | wg rh intensity-contrast lingual | GCST90003839 | 5.21 |
| 2911 | F12 levels | GCST90469166 | 5.21 |
| 2912 | SNX5 levels | GCST90470702 | 5.20 |
| 2913 | X-14626 levels | GCST90243861 | 5.19 |
| 2914 | CLEC1B/LGALS8 ratio | GCST90314096 | 5.19 |
| 2915 | Cholesterol in Large LDL | GCST90497923 | 5.19 |
| 2916 | Comorbidity of gastric and duodenal ulcers | GCST90270929 | 5.19 |
| 2917 | FCRLB levels | GCST90469210 | 5.19 |
| 2918 | 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels | GCST90200083 | 5.19 |
| 2919 | CD5L levels | GCST90468640 | 5.18 |
| 2920 | Liver volume | GCST90016666 | 5.18 |
| 2921 | LDL direct, adjusted by medication | Lipid or lipoprotein measurement | UKBB00000387 | 5.18 |
| 2922 | Central pulse pressure | GCST90267387 | 5.18 |
| 2923 | ASGR2 levels | GCST90468376 | 5.17 |
| 2924 | Placental weight (paternal genotype, adjusted for sex and gestational age) | GCST90275191 | 5.17 |
| 2925 | Other diseases of upper respiratory tract | FING00001012 | 5.16 |
| 2926 | NPHS1 levels | GCST90470070 | 5.16 |
| 2927 | Phospholipids in medium VLDL (UKB data field 23504) | GCST90269601 | 5.16 |
| 2928 | CX3CL1/EPHB6 ratio | GCST90314324 | 5.16 |
| 2929 | GZMA/IL12A_IL12B ratio | GCST90315009 | 5.16 |
| 2930 | IL12A_IL12B/LAG3 ratio | GCST90315147 | 5.15 |
| 2931 | CRTAP levels | GCST90468872 | 5.15 |
| 2932 | Bone marrow fat fraction of thoracic vertebra 12 | GCST90652384 | 5.14 |
| 2933 | aseg rh intensity Cerebellum-Cortex | GCST90003781 | 5.13 |
| 2934 | REST UKBBICA NODEamps25 0006 | GCST90385489 | 5.13 |
| 2935 | Triglycerides in very small VLDL | GCST90500873 | 5.13 |
| 2936 | Metabolic syndrome | GCST90444489 | 5.13 |
| 2937 | SIAE/SNAP29 ratio | GCST90315843 | 5.13 |
| 2938 | Heart failure and bmi 25plus | FING00000603 | 5.13 |
| 2939 | Chronic lung diseases including COPD, Emphysema and Bronchitis | GCST90475272 | 5.13 |
| 2940 | ROR1/TNFRSF21 ratio | GCST90315787 | 5.11 |
| 2941 | HYOU1/THBD ratio | GCST90315106 | 5.10 |
| 2942 | SERPINA4 levels | GCST90470584 | 5.10 |
| 2943 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T313 | ECGU000313 | 5.10 |
| 2944 | Cardiac conduction disorders (PheCode 426) | GCST90475952 | 5.10 |
| 2945 | Saturated fatty acids levels | GCST90499953 | 5.09 |
| 2946 | 1-stearoyl-gpc (18:0) levels | GCST90199732 | 5.09 |
| 2947 | ANXA3/HCLS1 ratio | GCST90313282 | 5.09 |
| 2948 | Birth weight known - Yes - pounds and ounces | Early life factors | UKBB00000097 | 5.09 |
| 2949 | DDR1 levels | GCST90468970 | 5.07 |
| 2950 | AHNAK levels | GCST90468261 | 5.07 |
| 2951 | Cholesteryl esters to total lipids ratio in medium LDL | GCST90092907 | 5.07 |
| 2952 | F9/PROC ratio | GCST90314748 | 5.07 |
| 2953 | IDP dMRI TBSS L3 Posterior corona radiata L | GCST90004198 | 5.06 |
| 2954 | Omega-3 fatty acids to total fatty acids percentage | GCST90502451 | 5.06 |
| 2955 | DTI TBSS MD Anterior corona radiata R | GCST90384594 | 5.06 |
| 2956 | TCL1A levels | GCST90470817 | 5.05 |
| 2957 | FLT1 levels | GCST90469249 | 5.05 |
| 2958 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 5.05 |
| 2959 | DKK1/ZBTB16 ratio | GCST90314486 | 5.04 |
| 2960 | IDP dMRI TBSS ICVF Anterior limb of internal capsule R | GCST90004343 | 5.04 |
| 2961 | aparc-a2009s rh thickness Pole-temporal | GCST90003719 | 5.03 |
| 2962 | Urine taurodeoxycholic acid 3-sulfate levels in chronic kidney disease | GCST90266045 | 5.02 |
| 2963 | IFNGR1/THBD ratio | GCST90315130 | 5.02 |
| 2964 | DTI autoptx FA str r tract | GCST90385136 | 5.01 |
| 2965 | Salad leaves liking | GCST90094823 | 5.01 |
| 2966 | PCBD1 levels | GCST90470166 | 5.01 |
| 2967 | CHL1 levels | GCST90468745 | 5.01 |
| 2968 | CTSZ/NAAA ratio | GCST90314320 | 5.00 |
| 2969 | Bone marrow fat fraction of lumbar vertebra 5 | GCST90652390 | 5.00 |
| 2970 | aseg lh intensity Putamen | GCST90003770 | 5.00 |
| 2971 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502644 | 4.99 |
| 2972 | Volume of left whole amygdala | GCST90474986 | 4.99 |
| 2973 | TIRAP levels | GCST90243032 | 4.99 |
| 2974 | wg lh intensity-contrast parstriangularis | GCST90003811 | 4.99 |
| 2975 | SPINT1 levels | GCST90241717 | 4.98 |
| 2976 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T228 | ECGU000228 | 4.98 |
| 2977 | CA9 levels | GCST90468518 | 4.98 |
| 2978 | BA-exvivo rh area BA4p | GCST90003226 | 4.97 |
| 2979 | TSC1 levels | GCST90470972 | 4.96 |
| 2980 | CASP10 levels | GCST90468542 | 4.96 |
| 2981 | CD69/CEP43 ratio | GCST90313867 | 4.96 |
| 2982 | CD69/PPP1R2 ratio | GCST90313882 | 4.96 |
| 2983 | LBR/POLR2F ratio | GCST90315297 | 4.96 |
| 2984 | FADD/PPP1R2 ratio | GCST90314774 | 4.96 |
| 2985 | Linoleic acid levels | GCST90502310 | 4.95 |
| 2986 | CCN2 levels | GCST90468588 | 4.95 |
| 2987 | ADH4/SCLY ratio | GCST90313195 | 4.95 |
| 2988 | Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583) | GCST90269680 | 4.95 |
| 2989 | TNFRSF11B levels | GCST90012002 | 4.95 |
| 2990 | Free cholesterol to total lipids in IDL percentage (UKB data field 23612) | GCST90269709 | 4.94 |
| 2991 | AKT1S1 levels | GCST90468276 | 4.94 |
| 2992 | wg rh intensity-contrast parahippocampal | GCST90003842 | 4.93 |
| 2993 | IDP dMRI ProbtrackX ICVF cgh l | GCST90004381 | 4.93 |
| 2994 | Lymphocyte count | GCST90002316 | 4.93 |
| 2995 | CDHR2/SSC4D ratio | GCST90313965 | 4.92 |
| 2996 | CCL13/CCL2 ratio | GCST90313675 | 4.91 |
| 2997 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 4.91 |
| 2998 | COLEC12/TAFA5 ratio | GCST90314185 | 4.91 |
| 2999 | AXIN1/GOPC ratio | GCST90313407 | 4.91 |
| 3000 | FOXO1/NFATC1 ratio | GCST90314873 | 4.91 |